Oscotec Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
21,859
17,110
18,336
3,554
3,908
Cost of Goods Sold (COGS) incl. D&A
12,886
9,912
10,246
1,797
2,028
Gross Income
8,973
7,198
8,090
1,757
1,880
SG&A Expense
9,858
7,954
7,173
3,435
3,438
EBIT
885
756
681
1,740
1,669
Unusual Expense
2,364
897
75
745
2,025
Non Operating Income/Expense
163
21
353
3,234
106
Interest Expense
620
596
726
754
485
Pretax Income
3,827
2,110
302
4,906
4,276
Income Tax
110
54
61
37
-
Consolidated Net Income
3,937
2,057
363
4,869
4,276
Net Income
3,971
2,022
395
4,114
3,893
Net Income After Extraordinaries
3,971
2,022
395
4,582
3,893
Net Income Available to Common
3,971
2,022
395
3,646
3,893
EPS (Basic)
183.00
90.00
17.00
144.00
147.00
Basic Shares Outstanding
22
22
24
25
27
EPS (Diluted)
182.53
90.37
16.17
143.71
146.85
Diluted Shares Outstanding
22
22
24
25
27
EBITDA
476
344
1,194
1,401
1,296
Other Operating Expense
-
-
237
61
112
Non-Operating Interest Income
206
119
70
77
9
Minority Interest Expense
34
34
32
755
383

About Oscotec

View Profile
Address
9/F, Korea Bio Park A
Seongnam GY 13488
Korea, Republic Of
Employees -
Website http://www.oscotec.com
Updated 09/14/2018
Oscotec, Inc. engages in the development and manufacture of pharmaceutical products. Its products include drugs for osteoporosis, arthritis, periodontal disease and cancer; functional food ingredients, dental bone graft materials, dental membrane and dental supplies. The company was founded on December 8, 1998 and is headquartered in Seongnam, South Korea.